The Cooper Companies, Inc.(COO) Stock Research - Grey Stern Research
Loading...

The Cooper Companies, Inc. (COO) Stock Analysis

$79.51 (1.64%)

COO Financial Performance


Use the table below to view The Cooper Companies, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2025

Metric Value Ranking among Peers
Price $79.51 -
52 Week Low $69.81 -
52 Week High $112.38 -
Market Cap $15.9 Billion 3/14
Gross Margin 68% 1/14
Profit Margin 11% 5/14
EBITDA margin 19% 6/14
Q1 - 2025 Revenue $964.7 Million 5/14
Q1 - 2025 Earnings $104.3 Million 5/14
Q1 - 2025 Free Cash Flow $101.2 Million 7/14
Trailing 4 Quarters Revenue $3.9 Billion 5/14
Trailing 4 Quarters Earnings $415.4 Million 5/14
Quarterly Earnings Growth 28% 6/14
Annual Earnings Growth 24% 5/14
Quarterly Revenue Growth 0% 12/14
Annual Revenue Growth 41% 1/14
Cash On Hand $100.9 Million 12/14
Short Term Debt $49.7 Million 6/14
Long Term Debt $2.5 Billion 3/14

The Cooper Companies, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare The Cooper Companies, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 38.28 3/14
PS 4.05 4/14
PB 1.96 10/14
PC 157.59 1/14
Liabilities to Equity 0.50 11/14
ROA 0.03 7/14
ROE 0.05 8/14
Current Ratio 2.98 3/14
Quick Ratio 0.02 12/14
Long Term Debt to Equity 0.31 8/14
Debt to Equity 0.31 8/14
Burn Rate 12.98 3/14
Cash to Cap 0.01 12/14
CCR 0.97 6/14
EV to EBITDA 100.77 4/14
EV to Revenue 4.67 4/14

Company Details

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

CEO: Mr. Albert White

Website: https://www.coopercos.com

Address: 6101 Bollinger Canyon Rd Ste 500 San Ramon, CALIFORNIA

Exchange: New York Stock Exchange

Industry: Medical Instruments & Supplies

The Cooper Companies, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to The Cooper Companies, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Becton, Dickinson and Company BDX $57.1 Billion
Hologic, Inc. HOLX $12.9 Billion
ResMed Inc. RMD $31.3 Billion
Haemonetics Corporation HAE $2.9 Billion
Teleflex Incorporated TFX $5.8 Billion
West Pharmaceutical Services, Inc. WST $14.6 Billion
Merit Medical Systems, Inc. MMSI $5.4 Billion
AngioDynamics, Inc. ANGO $386.6 Million
ICU Medical, Inc. ICUI $3.4 Billion
Repligen Corporation RGEN $7.3 Billion
AptarGroup, Inc. ATR $9.5 Billion
Envista Holdings Corporation NVST $2.6 Billion
Bausch + Lomb Corporation BLCO $4.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
COO Income Statements
Quarter Year Revenue Earnings
Q1 2025 $ 964.7 Million $104.3 Million
Q4 2024 $ 1.0 Billion $117.5 Million
Q3 2024 $ 1.0 Billion $104.7 Million
Q2 2024 $ 942.6 Million $88.9 Million
Q1 2024 $ 0 $81.2 Million
Q4 2023 $ 927.1 Million $84.5 Million
Q3 2023 $ 930.2 Million $85.3 Million
Q2 2023 $ 877.4 Million $39.8 Million

View All

COO Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2025 $100.9 Million $12.2 Billion $2.5 Billion $8.1 Billion
Q4 2024 $107.6 Million $12.3 Billion $2.6 Billion $8.1 Billion
Q3 2024 $109.9 Million $12.1 Billion $2.6 Billion $7.9 Billion
Q2 2024 $112.6 Million $12.0 Billion $2.7 Billion $7.8 Billion
Q1 2024 $135.2 Million $12.0 Billion $2.8 Billion $7.7 Billion
Q4 2023 $120.8 Million $11.7 Billion $2.6 Billion $7.6 Billion
Q3 2023 $117.3 Million $11.7 Billion $2.6 Billion $7.5 Billion
Q2 2023 $111.9 Million $11.5 Billion $2.6 Billion $7.4 Billion

View All

COO Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2025 $101.2 Million -$89.4 Million -$6.7 Million
Q4 2024 $128.1 Million -$140.0 Million -$2.1 Million
Q3 2024 $118.5 Million -$89.0 Million -$2.7 Million
Q2 2024 $36.9 Million -$74.1 Million -$22.7 Million
Q1 2024 $0 $0 $0
Q4 2023 $29.2 Million -$145.0 Million $3.4 Million
Q3 2023 $16.8 Million $0 $16.8 Million
Q2 2023 $50.6 Million -$73.6 Million -$6.4 Million

View All